Intellectual Property Law and Copyright Laws

During our live session, nearly 80% of attendees said they could see themselves using AI tools to assist with reviewing trademark search results.

Living in the attention economy makes change a constant. Businesses need to adapt and evolve. And what is more in need of a change than a company's main attention-grabbing arsenal? It's trademarks. But let's rewind for a moment.

With the continued growth of e-commerce, companies who conduct business online are increasingly more at risk of Intellectual Property (IP) infringement.

A patent claim needs to be novel and comprise an inventive step in view of what was public "prior art" before the filing date (or priority date) of the patent application.

Dans la décision PC-CoA-002/2025, la cour d'appel de la JUB vient de confirmer qu'il était possible pour le Titulaire d'un brevet européen délivré d'obtenir des mesures de conservation...

Extensions are granted only in justified exceptional circumstances to ensure efficient proceedings.

The European Commission issued an informal guidance letter to the Automotive Licensing Negotiation Group (ALNG), marking the first application of the Informal Guidance Notice...

The European Commission has issued its first-ever informal approvals of two separate sustainability initiatives among rivals under its revised Informal Guidance Notice and provided guidance on how the companies...

The past few years' rapid increase in the importance of software, data, and AI to drive new products and service offerings has brought a new set of IP challenges for many industrial companies.

On 9 February 2012, the Court of Justice of the European Union (the "ECJ") answered a preliminary question referred to it by the High Court of Justice of England and Wales (the "Referring Court") in Novartis AG ("Novartis") v. Actavis UK Ltd.

A recently published decision of the European Patent Office’s (EPO) Board of Appeal about European patents and clinical trials provides for interesting reading and for some important pointers about how to deal with clinical trials for medicinal products but also for medical devices as to not destroy novelty of a patentable invention with invalidity as result.

The patent of Oliver Brüstle that is at stake relates to purified neural precursor cells and to processes for their production from embryonic stem cells.